Read More

Mydecine’s Prospectus Supplement Closing Under Share Subscription And Management Update

Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor dated this past March 10, it has filed a shelf prospectus supplement to its final base shelf prospectus for th

MYCOF

Read More

9 Meters Biopharma Announces Management Change And Provides Clinical Update On Vurolenatide In Patients With Short Bowel Syndrome; John Temperato Resigns As President And Chief Executive Officer Of The Company Effective Immediately

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the

NMTR